Janus kinase 3: A novel target for selective transplant immunosupression

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 613-629

  Podder, Hemangshu ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Immunosuppression; Janus kinase (Jak)3; Kidney transplantation

Indexed keywords

2 NAPTHYLVINYL KETONE; 4 (3', 5' DIBROMO 4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 PHENYLAMINO 6,7 DIMETHOXYQUINAZOLINE; CALCINEURIN INHIBITOR; CP 352 664; CP 690 550; CT 2576; CYCLOSPORIN; CYCLOSPORIN A; HYDROXYLAMINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 3; INTERLEUKIN 5; JANUS KINASE; JANUS KINASE 2; JANUS KINASE 3; KETONE DERIVATIVE; LEFLUNOMIDE; LYMPHOKINE; METHOTREXATE; METHYLXANTHINE DERIVATIVE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NC 1153; PNU 156804; PRODIGIOSIN; QUINAZOLINE DERIVATIVE; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; WHI 258; WHI P 97;

ACUTE GRAFT REJECTION; ANEMIA; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CROSS REACTION; DOSE RESPONSE; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIPID METABOLISM; LYMPHATIC SYSTEM; LYMPHOCYTE ACTIVATION; MONOTHERAPY; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; PLEIOTROPY; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; DRUG EVALUATION, PRECLINICAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; JANUS KINASE 2; JANUS KINASE 3; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MACACA FASCICULARIS; MANNICH BASES; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PHOSPHORYLATION; PRODIGIOSIN; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRROLES; RATS; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN-2; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 11144343254     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.613     Document Type: Review

References (87)

1. CALNE RY, WHITE DJ, THIRU S et al.: Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1978) 2:1323-1327.
2. KAHAN BD: Cyclosporine. N. Engl. J. Med. (1989) 321 1725-1738.
3. CALNE RY, COLLIER DS, LIM S et al.: Rapamycin for immunosuppression in organ allografting. Lancet (1989) 2:227.
4. KAHAN BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. For the Rapamune US Study Group. Lancet (2000) 356:194-202.
5. SOHN SJ, FORBUSH KA, NGUYEN N et al.: Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis. J. Immunol. (1998) 160:2130-2138.
6. VINCENTI F: Immunosuppression minimization: current and future trends in transplant immunosuppression. J. Am. Soc. Nephrol. (2003) 14:1940-1948.
7. SAEMANN MD, KELEMEN P, ZEYDA M et al.: CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when JAK3 activity is inhibited. Transplant. Proc. (2002) 43:1407-1408.
8. LI XC, IMA A, LI Y et al.: Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and tong-term islet allograft survival. J. Immunol. (2000) 164:1193-1199.
9. CHEN M, CHENG A, CHEN YQ et al.: The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc. Natl. Acad. Sci. USA (1997) 94:6910-6915.
10. RIEDY MC, DUTRA AS, BLAKE TB et al.: Genomic sequence, organization, and chromosomal localization of human JAK3. Genemics (1996) 37:57-61.
11. LEU JH, YAN SJ, LEE TF et al.: Complete genomic organization and promoter analysis of the round-spotted pufferfish JAK1, JAK2, JAK3, and TYK2 genes. DNA Cell Biol. (2000) 19:431-446.
12. GURNIAK CB, THOMIS DC, BERG LJ: Genomic structure and promoter region of the murine Janus-family tyrosine kinase, Jak3. DNA Cell Biol. (1997) 16:85-94.
13. LIU KD, GAFFEN SL, GOLDSMITH MA, GREENE WC: Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr. Biol. (1997) 7 817-826.
14. KIM JE, CHEN J: Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc. Natl. Acad. Sci. USA (2000) 97:14340-14345.
15. LUO H, DEAROLF CR: The JAK/STAT pathway and Drosophila development. Bioessays (2001) 23:1138-1147.
16. SUZUKI K, NAKAJIMA H, SAITO Y et al.: Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int. Immunol. (2000) 12:123-132.
17. CACALANO NA, MIGONE TS, BAZAN F et al.: Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J. (1999) 18 1549-1558.
18. CANDOTTI F, OAKES SA, JOHNSTON JA et al.: Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood (1997) 90:3996-4003.
19. RUSSELL SM, JOHNSTON JA, NOGUCHI M et al.: Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science (1994) 266:1042-1045.
20. THOMIS DC, BERG LJ: Peripheral expression of Jak3 is required to maintain T lymphocyte function. J. Exp. Med. (1997) 185 197-206.
21. WITTHUHN BA, SILVENNOINEN O, MIURA O et al.: Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature (1994) 370:153-157.
22. MIYAZAKI T, KAWAHARA A, FUJII H et al.: Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science (1994) 266:1045-1047.
23. TANG W, HUO H, ZHU J et al.: Critical sites for the interaction between IL-2R gamma and JAK3 and the following signaling. Biochem. Biophys. Res. Commun. (2001) 283:598-605.
24. THOMIS DC, BERG LJ: The role of Jak3 in lymphoid development, activation, and signaling. Curr. Opin. Immunol. (1997) 9 541-547.
25. ZHU MH, BERRY JA, RUSSELL SM, LEONARD WJ: Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta. J. Biol. Chem. (1998) 273:10719-10725.
26. NAKAMURA Y, RUSSELL SM, MESS SA et al.: Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature (1994) 369 330-333.
27. WAKAO H, GOUILLEUX F, GRONER B: Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. (1995) 14 854-855.
28. MARTINO A, HOLMES JH 4TH, LORD JD, MOON JJ, NELSON BH: Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J. Immunol. (2001) 166:1723-1729.
29. DARNELL JE Jr: STATs and gene regulation. Science (1997) 277:1630-1635.
30. ZHANG X, BLENIS J, LI HC, SCHINDLER C, CHEN-KIANG S: Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science (1995) 267:1990-1994.
31. WEN Z, ZHONG Z, DARNELL JE Jr: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell (1995) 82:241-250.
32. MORIGGL R, TOPHAM DJ, TEGLUND S et al.: Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (1999) 10:249-259.
33. SAIJO K, PARK SY, ISHIDA Y, ARASE H, SAITO T: Crucial role of Jak3 in negative selection of self-reactive T cells. J. Exp. Med. (1997) 185:351-356.
34. SUGAMURA K, ASAO H, KONDO M et al.: The common gamma-chain for multiple cytokine receptors. Adv. Immunol. (1995) 59:225-277.
35. WEN R, WANG D, MCKAY C et al.: Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. Mol. Cell. Biol. (2001) 21:678-689.
36. KUMAR A, COMMANE M, FLICKINGER TW, HORVATH CM, STARK GR: Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science (1997) 278: 1630-1632.
37. LI XC, STROM TB, TURKA LA, WELLS AD: T cell death and transplantation tolerance. Immunity (2001) 14:407-416.
38. SAAD MJ, CARVALHO CR, THIRONE AC, VELLOSO LA: Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. J. Biol. Chem. (1996) 271:22100-22104.
39. STEPKOWSKI SM, ERWIN-COHEN RA, BEHBOD F et al.: Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood (2002) 99:680-689.
40. SUDBECK EA, LIU XP, NARLA RK et al.: Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. (1999) 5:1569-1582.
41. UCKUN FM, EK O, LIU XP, CHEN CL: In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4′hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. Clin. Cancer Res. (1999) 5:2954-2962.
42. CETKOVIC-CVRLJE M, ROERS BA, WAURZYNIAK B, LIU XP, UCKUN FM: Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood (2001) 98:1607-1613.
43. UCKUN FM, ROERS BA, WAURZYNIAK B, LIU XP, CETKOVIC-CVRLJE M: Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood (2002) 99:4192-4199.
44. CETKOVIC-CVRLJE M, DRAGT AL, VASSILEV A, LIU XP, UCKUN FM: Targeting JAK3 with JANEX-1 for prevention of autoimmune Type 1 diabetes in NOD mice. Clin. Immunol. (2003) 106:213-225.
45. CETKOVIC-CVRLJE M, DRAGT AL, UCKUN FM: Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1). Arzneimittelforschung (2003) 53:648-654.
46. TIBBLES HE, VASSILEV A, WENDORF H et al.: Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J. Biol. Chem. (2001) 276:17815-17822.
47. TRIEU VN, LIU R, LIU XP, UCKUN FM: A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. (2000) 267:22-25.
48. MALAVIYA R, CHEN CL, NAVARA C et al.: Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′, 5′-dibromo-4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J. Pharmacol. Exp. Ther. (2000) 295:912-926.
49. VIHINEN M, VILLA A, MELLA P et al.: Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency, Clin. Immunol. (2000) 96:108-118.
50. ZHANG H, DESAI NN, OLIVERA A et al.: Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J. Cell Biol. (1991) 114:155-167.
51. CHAN AC, DALTON M, JOHNSON R et al.: Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function. EMBO J. (1995) 14 2499-2508.
52. WANGE RL, GUITIAN R, ISAKOV N et al.: Activating and inhibitory mutations in adjacent tyrosines in the kinase domain of ZAP-70. J. Biol. Chem. (1995) 270: 18730-18733.
53. KONG G, DALTON M, WARDENBURG JB et al.: Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function. Mol. Cell. Biol. (1996) 16:5026-5035.
54. BROWN GR, BAMFORD AM, BOWYER J et al.: Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg. Med. Chem. Lett (2000) 10:575-579.
55. WASIK MA, NOWAK I, ZHANG Q, SHAW LM: Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyldimethylxanthine. Leuk. Lymphoma (1998) 28:551-560.
56. PASCUAL J, ORTE J, MARCEN R, BURGOS J, ORTUNO J: Use of leflunomide in human renal transplantation. Transplantation (2001) 71:1709.
57. WILLIAMSON RA, YEA CM, ROBSON PA et al.: Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. (1995) 270:22467-22472.
58. MANNA SK, MUKHOPADHYAY A, AGGARWAL BB: Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. (2000) 165:5962-5969.
59. XU X, WILLIAMS JW, BREMER EG, FINNEGAN A, CHONG AS: Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. (1995) 270 2398-2403.
60. ELDER RT, XU X, WILLIAMS JW et al.: The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. (1997) 159 22-27.
61. MATTER T, KOCHRAR K, BARTLETT R, BREMER EG, FINNEGAN A: Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. (1993) 334:161.
62. HESS DA, O'LEARY EF, LEE JT et al.: Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole. FASEB J. (2001) 15:1855-1857.
63. CHANGELIAN PS, FLANAGAN ME, BALL DJ et al.: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science (2003) 302:875-878.
64. KUDLACZ E, PERRY B, SAWYER P et al.: The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant (2004) 4:51-57.
65. BORIE D, HAUSEN B, LARSON M et al.: A life-supporting technique of renal allotransplantation in Macaca fascicularis to evaluate novel immunosuppressive drugs in nonhuman primates. J. Surg. Res. (2002) 107:64-74.
66. HAUSEN B, KLUPP J, CHRISTIANS U et al.: Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation (2001) 72:1128-1137.
67. GAZIT A, YAISH P, GILON C, LEVITZKI A: Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. (1989) 32:2344-2352.
68. KLEINBERGER-DORON N, SHELAH N, CAPONE R, GAZIT A, LEVITZKI A: Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp. Cell Res. (1998) 241 340-351.
69. KIRKEN RA, ERWIN RA, TAUB D et al.: Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J. Leukoc. Biol. (1999) 65:891-899.
70. BEHBOD F, ERWIN-COHEN RA, WANG ME et al.: Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J. Immunol. (2001) 166:3724-3732.
71. AZUMA T, WATANABE N, YAGISAWA H et al.: Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant. Immunopharmacology (2000) 46:29-37.
72. TSUJI RF, MAGAE J, YAMASHITA M, NAGAI K, YAMASAKI M: Immunomodulating properties of prodigiosin 25-C, an antibiotic which preferentially suppresses induction of cytotoxic T cells. J. Antibiot. (1992) 45:1295-1302.
73. MAGAE J, MILLER MW, NAGAI K, SHEARER GM: Effect of metacycloprodigiosin, an inhibitor of killer T cells, on murine skin and heart transplants. J. Antibiot. (1996) 49:86-90.
74. STEPKOWSKI S, FURIAN L, JANCZEWSKA S et al.: Janus tyrosine kinase (Jak3) inhibitor, NC1153, induces apoptosis of T cells and donor-specific transplantation tolerance. Am. J. Transplant (2004) 4:185.
75. BENNETT WM: Insights into chronic cyclosporine nephrotoxicity. Int. J. Clin. Pharmacol. Ther. (1996) 34:515.
76. PODDER H, STEPKOWSKI SM, NAPOLI KL et al.: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J. Am. Soc. Nephrol. (2001) 12:1059-1071.
77. PODDER H, STEPKOWSKI S, VERANI R, KIRKEN R, KAHAN BD: Lack of nephrotoxic, lipotoxic, and myelotoxic side effects of NC1153, a new Janus Kinase 3 (Jak3) antagonist. 11th Congress of the European Society for Organ Transplantation (2003).
78. PODDER H, STEPKOWSKI SM, WANG M et al.: Selective Janus kinase 3 (Jak3) antagonist acts synergistically with cyclosporine (CsA) but lacks side effects associated with CaA/sirolimus combination. Am. J. Transplant (2004) 4:286.
79. KAHAN BD, GIBBONS S, TEJPAL N, STEPKOWSKI SM, CHOU TC: Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation (1991) 51:232-239.
80. STEPKOWSKI SM, NAPOLI KL, WANG ME et al.: Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation (1996) 62:986-994.
81. ZIMMERMAN J, KAHAN BD: Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J. Clin. Pharmacol. (1997) 37:405-415.
82. NAPOLI KL, WANG ME, STEPKOWSKI SM, KAHAN BD: Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther. Drug Monit. (1998) 20:123-133.
83. KAHAN BD, KRAMER WG: Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin. Pharmacol. Ther. (2001) 70:74-81.
84. HITCHINGS GH: Biochemical background of trimethoprin-sulphamethoxazole. Med. J. Aust. (1973) 1:5-9.
85. MURGIA MG, JORDAN S, KAHAN BD: The side effect profile of sirolimus: a Phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. (1996) 49:209-216.
86. MORRISETT JD, ABDEL-FATTAH G, HOOGEVEEN R et al.: Effect of sirolimus on plasma lipids and lipoprotein levels in renal transplant patients. Transplantation (1999) 67:S60.
87. SAEMANN MD, ZEYDA M, DIAKOS C et al.: Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation (2003) 75:1864-1872.